In the latest twist in the ocean of Zantac-related litigation playing out across state courts, drugmakers have notched a key ...

Delaware's top court reversed a ruling that allowed expert testimony in Zantac cancer lawsuits, citing improper legal ...

Delaware's Supreme Court sides with drugmakers including GSK (GSK) and Pfizer (PFE), rejecting expert testimony linking ...

The Delaware Supreme Court rejected the legitimacy of expert testimony linking the heartburn drug Zantac to cancer, in a ...

Delaware's highest court ruled on Thursday that patients suing drugmakers GSK, Pfizer, Sanofi and Boehringer Ingelheim cannot ...

Boehringer Ingelheim recently announced the start of the THULITE phase II clinical study ( NCT06962839 ). THULITE will ...

Boehringer Ingelheim Pharma GmbH & Co KG has selected a third oncology drug candidate to advance into IND-enabling studies under its ongoing collaboration with Oxford Biotherapeutics Ltd.

Joshua K. Sabari, MD, of NYU Langone Health discusses promising results for zongertinib in HER2-mutant NSCLC; the tyrosine ...

Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming that its discontinued heartburn drug Zantac caused cancer, both of which had previously ended with hung juries.

A trial ended with a hung jury on Thursday in a California man's lawsuit alleging Boehringer Ingelheim's discontinued heartburn drug Zantac gave him bladder cancer.

Boehringer Ingelheim, GSK, Pfizer and Sanofi all sold brand name Zantac at various times since it was approved in 1983, and have been named in tens of thousands of lawsuits over the alleged cancer ...

Boehringer Ingelheim, GSK, Pfizer and Sanofi all sold brand name Zantac at various times since it was approved in 1983, and have been named in tens of thousands of lawsuits over the alleged cancer ...